By Maria Armental
Edwards Lifesciences Corp. raised sales projections for the year, following stronger-than-expected second-quarter results.
The company now expects $5.2 billion to $5.4 billion in sales, up from its previous view of $4.9 billion to $5.3 billion in sales, and expects adjusted profit at the high end of the previous range of $2.07 to $2.27 a share.
This quarter, the medical-device company expects 50 cents to 56 cents a share in adjusted profit and $1.29 billion to $1.37 billion in sales, compared with analysts' projected 55 cents a share in profit and $1.3 billion in sales, according to FactSet.
"As patients and clinicians increasingly recognize the significant benefits of our less-invasive therapies, supported by the growing body of compelling evidence, we remain optimistic about the long-term growth opportunity," Chief Executive Michael A. Mussallem said in a statement.
Write to Maria Armental at firstname.lastname@example.org
(END) Dow Jones Newswires